{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n Recent studies have revealed that the long noncoding RNA LINC01260 plays a context‐dependent regulatory role in human disease. In non‐small cell lung cancer (NSCLC), LINC01260 is significantly downregulated in tumor tissues and cell lines, an alteration that correlates with poorer patient survival. Functional assays demonstrated that reduced LINC01260 levels promote NSCLC cell proliferation, colony formation, migration, and in vivo tumor growth, while its knockdown also inhibits apoptosis via modulation of Bcl‐2/Bax protein expression. Mechanistically, LINC01260 acts as a competing endogenous RNA by sponging miR-562, which in turn relieves the repression of the deubiquitinating enzyme CYLD. The subsequent upregulation of CYLD dampens NF-κB signaling, evidenced by decreased NF-κB activity and reduced p65 expression, thus restraining malignant progression."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n In a separate study focused on nonalcoholic fatty liver disease (NAFLD), LINC01260 was found to be downregulated in oleic acid-induced steatotic LO2 hepatocytes. Overexpression of LINC01260 significantly reduced lipid droplet formation, suggesting an inhibitory effect on cellular steatosis. Bioinformatics and experimental validation further implicated LINC01260 in the regulation of RXRB expression, where its overexpression induced RXRB transcription and translation. Silencing of RXRB attenuated the lipid-lowering effects mediated by LINC01260, indicating that LINC01260 may function as a competing endogenous RNA to regulate the adipocytokine signaling pathway through RXRB."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Collectively, these findings indicate that LINC01260 contributes to disease modulation by acting as a molecular sponge for specific microRNAs, thereby influencing key downstream targets such as CYLD in NSCLC and RXRB in NAFLD. This dual role in controlling cell proliferation and lipid metabolism highlights the therapeutic potential of targeting LINC01260 in diverse pathological contexts.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Yangming Chen, Yujie Lei, Jianbin Lin, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The LINC01260 Functions as a Tumor Suppressor via the miR-562/CYLD/NF-κB Pathway in Non-Small Cell Lung Cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Onco Targets Ther (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2147/OTT.S253730"}], "href": "https://doi.org/10.2147/OTT.S253730"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33116647"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33116647"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Xiaoxiao Ge, Tao Sun, Yanmei Zhang, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The role and possible mechanism of the long noncoding RNA LINC01260 in nonalcoholic fatty liver disease."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nutr Metab (Lond) (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1186/s12986-021-00634-4"}], "href": "https://doi.org/10.1186/s12986-021-00634-4"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "35016686"}], "href": "https://pubmed.ncbi.nlm.nih.gov/35016686"}]}]}]}